Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
NCT04929379Phase 2Active, not recruiting
- Sponsor
- Alessandro Doria
- Start
- Jan 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic nephropathy (DN) comparing Fenofibrate with Placebo (2 arms). Primary endpoints: Isotopic Glomerular Filtration Rate at 84 weeks and Serum biomarkers of increased ESKD risk at 84 weeks. Started Jan 2022; status: active, not recruiting.
02
Drugs
fenofibrate
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04929379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929379.